IL248244B - Single-chain proteins are agonists of the TRAIL receptor - Google Patents
Single-chain proteins are agonists of the TRAIL receptorInfo
- Publication number
- IL248244B IL248244B IL248244A IL24824416A IL248244B IL 248244 B IL248244 B IL 248244B IL 248244 A IL248244 A IL 248244A IL 24824416 A IL24824416 A IL 24824416A IL 248244 B IL248244 B IL 248244B
- Authority
- IL
- Israel
- Prior art keywords
- receptor agonist
- agonist proteins
- chain trail
- trail
- chain
- Prior art date
Links
- 229940123369 TRAIL receptor agonist Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 | |
| PCT/US2015/027270 WO2015164588A1 (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL248244A0 IL248244A0 (en) | 2016-11-30 |
| IL248244B true IL248244B (en) | 2020-03-31 |
Family
ID=53055121
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL248244A IL248244B (en) | 2014-04-23 | 2016-10-07 | Single-chain proteins are agonists of the TRAIL receptor |
| IL272612A IL272612A (en) | 2014-04-23 | 2020-02-11 | Single-chain proteins are agonists of the TRAIL receptor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272612A IL272612A (en) | 2014-04-23 | 2020-02-11 | Single-chain proteins are agonists of the TRAIL receptor |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016257000B2 (en) | 2015-05-04 | 2020-05-14 | Apogenix Ag | Single-chain CD40-receptor agonist proteins |
| WO2017068180A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
| EP3364995B1 (en) | 2015-10-23 | 2021-08-04 | Apogenix AG | Single-chain cd27-receptor agonist proteins |
| CN108473549A (zh) * | 2015-10-23 | 2018-08-31 | 阿珀吉科吉尼科斯股份公司 | 单链gitr受体激动剂蛋白 |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| WO2017151707A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
| AU2017234679A1 (en) * | 2016-03-16 | 2018-08-30 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| KR20190017804A (ko) * | 2016-06-13 | 2019-02-20 | 메리맥 파마슈티컬즈, 인크. | 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법 |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| US11578315B2 (en) | 2017-08-11 | 2023-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig L-asparaginase variants and methods of use |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| TW202003553A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療癌症之abbv-621與抗癌劑之組合 |
| WO2021229103A2 (en) | 2020-05-15 | 2021-11-18 | Apogenix Ag | Multi-specific immune modulators |
| CA3217894A1 (en) | 2021-05-28 | 2022-12-01 | Gernot Stuhler | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR025984A1 (es) | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| SI1724284T1 (sl) | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2003091447A2 (en) | 2002-04-26 | 2003-11-06 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| ES2333358T3 (es) * | 2005-04-15 | 2010-02-19 | Rappaport Family Institute For Research In The Medical Sciences | Moleculas y metodos de uso de las mismas para el tratamiento de enfermedades asociadas con mcp-1/ccr2. |
| CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| EP2484691B1 (en) | 2007-07-10 | 2016-01-13 | Apogenix GmbH | TNF superfamily collectin fusion proteins |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| PL2604693T3 (pl) * | 2008-07-21 | 2016-09-30 | Jednołańcuchowe cząsteczki TNFSF | |
| JP2012502994A (ja) | 2008-09-22 | 2012-02-02 | アムジエン・インコーポレーテツド | 治療方法 |
| EP2379585A2 (en) * | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
| WO2010078966A1 (en) | 2009-01-09 | 2010-07-15 | Apogenix Gmbh | Fusion proteins forming trimers |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| KR20130056870A (ko) | 2010-04-13 | 2013-05-30 | 메디뮨 엘엘씨 | 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드 |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| AU2013291982B2 (en) * | 2012-07-18 | 2017-01-12 | Apogenix Ag | Shortened CD95-Fc variants |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272612A (en) | Single-chain proteins are agonists of the TRAIL receptor | |
| IL246355B (en) | p97–ids fused proteins | |
| SG11201704010UA (en) | Fibroin-derived protein composition | |
| GB201415344D0 (en) | Protein | |
| IL250502B (en) | New polypeptides | |
| PL3702450T3 (pl) | Białko | |
| GB201515745D0 (en) | Proteins | |
| GB201511787D0 (en) | Proteins | |
| IL248276A0 (en) | Carbohydrate binding proteins | |
| SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
| GB201513033D0 (en) | Proteins | |
| PL3099793T3 (pl) | Białko | |
| GB201517390D0 (en) | Protein variant analysis | |
| IL250999A0 (en) | Spiro-thiazolones | |
| GB201504048D0 (en) | Material sampler | |
| GB201412797D0 (en) | Proteins | |
| GB201412646D0 (en) | Proteins | |
| GB201412648D0 (en) | Proteins | |
| GB201412649D0 (en) | Proteins | |
| GB201406894D0 (en) | Proteins | |
| GB201405955D0 (en) | Proteins | |
| GB201405952D0 (en) | Proteins | |
| GB201403915D0 (en) | Proteins | |
| GB201403913D0 (en) | Proteins | |
| GB201403914D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB20 | Patent renewed for 20 years |